https://gbc.diversedesign.net/when-medicine-really-gets-personal-the-diy-clinical-trial/2012-03-31T07:20:15+00:00https://gbc.diversedesign.net/test-event-1/2012-04-01T10:33:00+00:00https://gbc.diversedesign.net/global-bioclinical-launches-new-website/2012-04-05T00:35:11+00:00https://gbc.diversedesign.net/1580/2012-04-05T00:56:50+00:00https://gbc.diversedesign.net/icd-10-likely-to-be-pushed-back-a-year/2012-04-12T05:33:11+00:00https://gbc.diversedesign.net/andrew-von-eschenbach-toward-a-21st-century-fda/2012-04-17T04:17:40+00:00https://gbc.diversedesign.net/britains-biobank-is-open-for-business/2012-04-19T06:42:55+00:00https://gbc.diversedesign.net/consent-2-0-a-better-way-of-signing-up-for-studies-of-your-genes/2012-05-01T15:32:08+00:00https://gbc.diversedesign.net/fast-growth-in-real-and-virtual-biobanks-may-be-revenue-opportunity-for-clinical-pathology-laboratories/2012-05-21T17:28:45+00:00https://gbc.diversedesign.net/global-bioclinical-welcomes-jennifer-maas-as-senior-consultant/2012-05-31T22:06:42+00:00https://gbc.diversedesign.net/biospecimens-and-biorepositories-for-the-community-pathologist/2012-06-12T03:28:06+00:00https://gbc.diversedesign.net/personalized-medicine-who-has-the-tissue/2012-06-12T03:29:23+00:00https://gbc.diversedesign.net/building-better-biobanks/2012-06-19T02:08:00+00:00https://gbc.diversedesign.net/fda-safety-innovation-act-step-forward-for-rare-diseases/2012-07-11T19:07:26+00:00https://gbc.diversedesign.net/tcga-reports-on-crc-analyses/2012-07-19T20:12:51+00:00https://gbc.diversedesign.net/obbrchangestobbrb/2012-10-04T20:53:50+00:00https://gbc.diversedesign.net/nci-publishes-gtex-sops-2/2012-07-31T19:04:37+00:00https://gbc.diversedesign.net/genetic-alliance-biobank-boot-camp/2012-08-03T19:10:56+00:00https://gbc.diversedesign.net/curetis-ag-trial-in-us/2012-12-07T12:54:12+00:00https://gbc.diversedesign.net/epigenomics-reports-non-inferiority-of-blood-based-crc-test/2012-12-07T13:23:54+00:00https://gbc.diversedesign.net/epigenomics-provides-additional-data-on-head-to-head-comparison-study/2012-12-20T15:54:18+00:00https://gbc.diversedesign.net/us-biobank-survey/2013-01-28T14:55:58+00:00https://gbc.diversedesign.net/ama-enhances-nih-genetic-testing-registry/2013-04-25T18:02:20+00:00https://gbc.diversedesign.net/global-bioclinical-supports-publication-in-biopreservation-and-biobanking-for-research-tissue-recovery-best-practices/2013-04-25T18:30:40+00:00https://gbc.diversedesign.net/cancer-centers-racing-to-map-genes/2013-04-25T18:56:16+00:00https://gbc.diversedesign.net/genomic-studies-unlock-details-on-two-cancers/2013-05-01T20:53:29+00:00https://gbc.diversedesign.net/gbc-attends-2013-asm-conference/2013-05-22T07:38:32+00:00https://gbc.diversedesign.net/lung-cancer-screening-most-useful-in-high-risk-people/2013-07-19T15:23:59+00:00https://gbc.diversedesign.net/tcga-changes-the-oncology-landscape/2013-10-04T17:54:29+00:00https://gbc.diversedesign.net/curetis-icaac-2013-poster/2013-10-04T18:19:24+00:00https://gbc.diversedesign.net/researchers-aim-speed-cures-patients/2014-01-09T18:32:39+00:00https://gbc.diversedesign.net/fda-panel-votes-colorectal-cancer-test/2014-03-27T17:19:24+00:00https://gbc.diversedesign.net/curetis-miniature-dna-lab-video/2014-04-17T15:46:43+00:00https://gbc.diversedesign.net/gbc-attends-2014-asm-conference/2014-05-19T17:51:37+00:00https://gbc.diversedesign.net/epigenomics-announces-publications/2014-06-24T20:02:40+00:00https://gbc.diversedesign.net/smart-molecular-diagnostic-tools-target/2014-09-15T13:37:50+00:00https://gbc.diversedesign.net/curetis-presents-new-unyvero-data/2014-09-30T13:53:37+00:00https://gbc.diversedesign.net/cancer-evolve-protect-us/2014-10-06T14:24:27+00:00https://gbc.diversedesign.net/800-cancer-medicines-development/2014-10-08T18:49:09+00:00https://gbc.diversedesign.net/curetis-joins-epjic/2014-10-09T15:37:16+00:00https://gbc.diversedesign.net/amp-members-reiterate-position-ldts/2014-11-18T18:42:55+00:00https://gbc.diversedesign.net/china-approves-epigenomics-colorectal-cancer-test/2014-12-08T17:27:45+00:00https://gbc.diversedesign.net/abbott-iridica-sytem-video/2015-01-21T18:10:17+00:00https://gbc.diversedesign.net/curetis-product-update/2015-02-23T16:23:02+00:00https://gbc.diversedesign.net/curetis-initiates-ce-performance-evaluation/2015-03-09T14:46:50+00:00https://gbc.diversedesign.net/curetis-second-gen-test-set-to-launch/2015-04-20T14:12:21+00:00https://gbc.diversedesign.net/epigenomics-wins-grant-for-lung-cancer-biomarker/2015-04-30T16:38:05+00:00https://gbc.diversedesign.net/epigenomics-reaches-99-5-adherence-for-epi-procolon-in-admit-study/2015-05-08T15:16:17+00:00https://gbc.diversedesign.net/maldi-in-microbiology/2015-05-19T15:10:24+00:00https://gbc.diversedesign.net/curertis-unyvero-used-for-novel-antibiotic-phase-iii-trial-in-eu/2015-06-24T14:31:43+00:00https://gbc.diversedesign.net/curetis-initiates-next-phase-us-fda-trial/2015-07-08T15:07:29+00:00https://gbc.diversedesign.net/epigenomics-announces-inclusion-of-test-in-chinese-screening-guideline/2015-07-15T15:51:33+00:00https://gbc.diversedesign.net/organoids-in-living-biobank/2015-08-12T14:46:26+00:00https://gbc.diversedesign.net/curetis-expands-distribution-to-greater-china/2015-09-25T14:36:53+00:00https://gbc.diversedesign.net/unyvero-ivd-for-antibiotic-resistance/2015-09-28T19:38:56+00:00https://gbc.diversedesign.net/sepsis-ivd-for-asean-distribution/2015-10-05T15:04:48+00:00https://gbc.diversedesign.net/epigenomics-update-at-amp-2015-annual-meeting/2015-11-03T15:40:47+00:00https://gbc.diversedesign.net/vari-biorepository-supports-nci-cptac/2015-11-05T15:41:42+00:00https://gbc.diversedesign.net/fda-request-for-epigenomics-crc-test-approval/2015-11-05T15:45:15+00:00https://gbc.diversedesign.net/hopkins-cepheid-breast-cancer-dx/2015-11-13T16:04:51+00:00https://gbc.diversedesign.net/isber-international-biorepository-locator/2015-12-14T15:45:27+00:00https://gbc.diversedesign.net/epigenomics-receives-fda-notice-of-epi-procolon-pending-approval/2016-01-08T16:42:54+00:00https://gbc.diversedesign.net/curetis-ipo/2015-11-10T16:57:15+00:00https://gbc.diversedesign.net/curetis-medical-advisory-board/2016-01-12T15:32:32+00:00https://gbc.diversedesign.net/curetis-expand-commercial-team/2016-02-03T16:13:17+00:00https://gbc.diversedesign.net/asterand-awarded-nih-cptac-contract/2016-02-16T17:09:49+00:00https://gbc.diversedesign.net/curetis-validation-of-blood-culture-cartridge/2016-02-23T16:09:45+00:00https://gbc.diversedesign.net/community-hospitals-time-tissue-handling/2016-03-01T16:53:04+00:00https://gbc.diversedesign.net/nih-precision-medicine-initiative/2016-03-03T06:31:03+00:00https://gbc.diversedesign.net/curetis-blood-culture-ce-ivd/2016-03-06T19:56:27+00:00https://gbc.diversedesign.net/curetis-launch-ce-ivd-unyvero-blood-culture-application-cartridge-eccmid-2016/2016-03-24T10:25:46+00:00https://gbc.diversedesign.net/2153/2016-03-24T22:20:18+00:00https://gbc.diversedesign.net/mers-cov-vaccine-derived-dromedaries/2016-03-25T18:34:13+00:00https://gbc.diversedesign.net/epigenomics-lung-cancer-test-china/2016-03-30T15:49:13+00:00https://gbc.diversedesign.net/global-bioclinical-awarded-nci-clinical-proteomics-tumor-analysis-consortium-cptac-contract/2016-03-31T18:55:54+00:00https://gbc.diversedesign.net/cryoport-coldchain-logistics-proteogenex/2016-04-05T13:55:12+00:00https://gbc.diversedesign.net/biochain-acquires-rights-lung-cancer-ivd-china/2016-04-07T15:26:01+00:00https://gbc.diversedesign.net/whole-genome-study-finds-six-types-liver-cancer/2016-04-13T15:52:36+00:00https://gbc.diversedesign.net/curetis-publishes-financial-results-2016-guidance/2016-04-13T15:59:04+00:00https://gbc.diversedesign.net/epigenomics-receives-fda-approval-epi-procolon/2016-04-13T16:01:47+00:00https://gbc.diversedesign.net/fda-finds-epigenomics-appealing/2016-04-14T01:37:09+00:00https://gbc.diversedesign.net/first-blood-test-crc/2016-04-14T16:56:48+00:00https://gbc.diversedesign.net/chinese-fda-names-septin9-crc-test-innovative-product/2016-05-02T13:50:54+00:00https://gbc.diversedesign.net/quintiles-ims-merge/2016-05-03T14:09:17+00:00https://gbc.diversedesign.net/labcorp-announces-launch-epi-procolon/2016-05-09T17:57:20+00:00https://gbc.diversedesign.net/seattle-international-hub/2016-05-16T14:26:13+00:00https://gbc.diversedesign.net/curetis-update/2016-05-20T15:20:31+00:00https://gbc.diversedesign.net/curetis-and-axonlab-distribution-agreement/2016-06-06T21:42:32+00:00https://gbc.diversedesign.net/epi-procolon-included-in-uspstf-guidelines/2016-06-16T15:28:26+00:00https://gbc.diversedesign.net/curetis-ce-ivd-blood-culture-cartridge/2016-06-17T15:20:38+00:00https://gbc.diversedesign.net/curetis-sepsis-detection-24-hrs-faster/2016-06-20T23:57:53+00:00https://gbc.diversedesign.net/curetis-completes-enrollment-in-unyvero-fda-trial/2016-06-28T13:49:59+00:00https://gbc.diversedesign.net/curetis-usa-inc-ceo-and-subsidiary/2016-07-05T13:50:23+00:00https://gbc.diversedesign.net/curetis-next-gen-implant-and-tissue-infection-cartridge/2016-09-06T14:59:49+00:00https://gbc.diversedesign.net/curetis-acquires-rights-to-siemens-database/2016-09-07T15:39:34+00:00https://gbc.diversedesign.net/potential-blood-for-early-alzheimers-disease/2016-09-09T14:37:17+00:00https://gbc.diversedesign.net/cancer-moonshot-blue-ribbon-panel-report/2016-09-12T15:30:45+00:00https://gbc.diversedesign.net/phage-therapy-trial-presses-on/2016-09-22T14:58:52+00:00https://gbc.diversedesign.net/ivd-market-to-reach-81b-by-2022/2016-09-28T18:41:14+00:00https://gbc.diversedesign.net/eua-for-zika-test/2016-09-29T15:10:03+00:00https://gbc.diversedesign.net/saliva-test-for-cancer/2016-09-29T15:22:48+00:00https://gbc.diversedesign.net/crc-detection-legislation/2016-09-30T14:19:57+00:00https://gbc.diversedesign.net/curetis-announces-positive-data-from-fda-trial/2016-10-25T14:53:59+00:00https://gbc.diversedesign.net/epigenomics-ag-jama-letter-to-editor/2016-10-27T15:20:41+00:00https://gbc.diversedesign.net/arup-offers-epi-procolon-blood-test/2016-11-08T17:39:03+00:00https://gbc.diversedesign.net/curetis-acquires-carpegen-rt-qpct-platform/2016-12-14T21:21:08+00:00https://gbc.diversedesign.net/curetis-completes-development-of-unyvero-cartridge-for-intra-abdominal-infections/2017-01-04T15:10:05+00:00https://gbc.diversedesign.net/curetis-files-for-u-s-fda-clearance-for-unyvero-platform-and-lower-respiratory-tract-lrt-application-cartridge/2017-01-05T15:31:15+00:00https://gbc.diversedesign.net/epi-procolon-blood-based-screening-for-colorectal-cancer-video/2017-01-11T18:51:50+00:00https://gbc.diversedesign.net/journal-of-cancer-treatment-and-research-communications-publishes-results-of-study-with-blood-test-epi-procolon/2017-01-12T17:54:27+00:00https://gbc.diversedesign.net/curetis-global-installed-base-expanding/2017-02-01T16:45:38+00:00https://gbc.diversedesign.net/epi-procolon-a-new-look-at-colon-cancer-screening-video/2017-02-02T17:27:26+00:00https://gbc.diversedesign.net/asterand-and-molecularmd-announce-partnership-for-biomarker-validation/2017-02-17T15:18:14+00:00https://gbc.diversedesign.net/epigenomics-joins-forces-to-increase-colorectal-cancer-screening-rates-in-the-united-states/2017-03-02T15:36:39+00:00https://gbc.diversedesign.net/u-s-department-of-veterans-affairs-awards-supply-contract-for-epi-procolon/2017-03-03T17:10:05+00:00https://gbc.diversedesign.net/computational-biologists-predict-antibiotic-resistances-using-biotech/2017-03-14T14:34:23+00:00https://gbc.diversedesign.net/curetis-starts-subsidiary-ares-genetics-to-advance-genetic-antibiotic-resistance-testing/2017-04-06T14:50:58+00:00https://gbc.diversedesign.net/fda-approves-23andmes-genetic-test-for-personal-disease-risks/2017-04-07T15:56:12+00:00https://gbc.diversedesign.net/curetis-to-present-data-from-unyvero-lrt-u-s-fda-clinical-trial-at-asm-microbe/2017-04-10T14:58:15+00:00https://gbc.diversedesign.net/curetis-unyvero-intra-abdominal-infection-iai-cartridge-receives-ce-marking/2017-04-21T19:35:18+00:00https://gbc.diversedesign.net/epigenomics-agrees-to-takeover-bid/2017-04-26T19:29:49+00:00https://gbc.diversedesign.net/recent-data-on-curetis-unyvero-iti-application-demonstrate-clinical-and-health-economic-benefits/2017-04-28T16:03:47+00:00https://gbc.diversedesign.net/curetis-provides-update-on-unyvero-lrt-fda-510k-submission/2017-05-24T14:36:12+00:00https://gbc.diversedesign.net/asterand-bioscience-expands-immuno-oncology-services-capabilities-with-vectra-polaris-imaging-system/2017-07-11T16:15:13+00:00https://gbc.diversedesign.net/bioreclamationivt-acquires-biospecimen-and-research-services-provider-asterand-bioscience/2017-08-11T17:45:49+00:00https://gbc.diversedesign.net/curetis-partners-with-biotest-to-support-academic-pepper-pentaglobin-peritonitis-trial-with-unyvero-iai-application/2017-08-15T19:43:58+00:00https://gbc.diversedesign.net/epigenomics-commences-post-approval-study-on-epi-procolon/2017-08-31T18:41:07+00:00https://gbc.diversedesign.net/mgi-and-curetis-to-collaborate-on-ngs-based-infectious-disease-diagnostics/2017-09-13T00:49:16+00:00https://gbc.diversedesign.net/epigenomics-initiates-e5-5m-private-placement/2017-09-21T21:25:09+00:00https://gbc.diversedesign.net/curetis-initiates-u-s-fda-study-for-unyvero-invasive-joint-infections-cartridge/2017-10-23T15:11:30+00:00https://gbc.diversedesign.net/curetis-publishes-update-for-the-first-nine-months-of-2017/2017-11-16T16:59:38+00:00https://gbc.diversedesign.net/epigenomics-ag-announces-recent-payment-decision-by-cms/2017-11-27T16:52:21+00:00https://gbc.diversedesign.net/key-tips-for-diagnostics-in-2018-and-beyond-development-success-in-the-evolving-us-and-eu-landscape/2017-11-30T14:55:00+00:00https://gbc.diversedesign.net/epigenomics-lung-cancer-test-receives-ce-ivd-mark/2017-12-20T16:23:42+00:00https://gbc.diversedesign.net/curetis-expects-near-term-fda-decision-on-de-novo-request-for-unyvero-lrt/2018-01-08T18:50:47+00:00https://gbc.diversedesign.net/dr-robert-w-day-fed-hutchinson-director-and-epigenomics-cmo/2018-01-08T20:21:25+00:00https://gbc.diversedesign.net/curetis-and-mgi-advance-strategic-partnership-in-ngs-based-molecular-microbiology/2018-01-10T20:06:29+00:00https://gbc.diversedesign.net/2020-is-the-new-hottest-date-in-genomics/2018-01-11T17:14:04+00:00https://gbc.diversedesign.net/liquid-biopsy-test-shows-promise-for-detecting-early-stage-colorectal-cancer/2018-01-17T16:12:56+00:00https://gbc.diversedesign.net/how-a-new-test-could-solve-a-costly-problem/2018-01-19T16:15:01+00:00https://gbc.diversedesign.net/federal-policy-for-the-protection-of-human-subjects-updated-common-rule/2018-01-19T17:17:13+00:00https://gbc.diversedesign.net/china-races-ahead-in-gene-editing-trials/2018-01-22T20:26:56+00:00https://gbc.diversedesign.net/next-gen-sequencing-ngs-finds-further-clinical-utility-in-oncology/2018-01-26T19:31:32+00:00https://gbc.diversedesign.net/curetis-unyvero-hospitalized-pneumonia-application-receives-singapore-health-sciences-authority-approval/2018-02-06T20:25:38+00:00https://gbc.diversedesign.net/curetis-expects-near-term-decision-by-fda-approving-first-product-in-us/2018-02-19T18:10:46+00:00https://gbc.diversedesign.net/curetis-subsidiary-ares-genetics-wins-incubator-stay-in-silicon-valley/2018-03-06T17:04:50+00:00https://gbc.diversedesign.net/curetis-receives-u-s-fda-de-novo-clearance-of-unyvero-system-and-unyvero-lrt-lower-respiratory-tract-infection-cartridge/2018-04-04T23:32:16+00:00https://gbc.diversedesign.net/curetis-unyvero-bcu-blood-culture-application-receives-approval-from-singapore-health-sciences-authority/2018-04-04T23:31:10+00:00https://gbc.diversedesign.net/curetis-launches-ce-ivd-marked-unyvero-urinary-tract-infection-uti-cartridge/2018-04-19T17:43:05+00:00https://gbc.diversedesign.net/hhs-delays-common-rule-for-another-six-months/2018-06-21T23:10:47+00:00https://gbc.diversedesign.net/epigenomics-ag-liquid-biopsy-test-for-liver-cancer-detection-to-obtain-ce-mark/2018-07-02T14:48:11+00:00https://gbc.diversedesign.net/fighting-antimicrobial-resistance-with-fast-molecular-diagnostics/2018-07-05T15:20:04+00:00https://gbc.diversedesign.net/seattles-indi-acquired-by-lung-cancer-tech-company-biodesix/2018-07-13T15:23:09+00:00https://gbc.diversedesign.net/the-new-era-of-medicine-www-innovation-org/2018-07-30T19:04:10+00:00https://gbc.diversedesign.net/epigenomics-posts-88-percent-increase-in-q2-revenues/2018-08-09T17:05:54+00:00https://gbc.diversedesign.net/curetis-subsidiary-ares-genetics-initiates-development-of-ai-powered-infectious-disease-test/2018-09-04T16:05:11+00:00https://gbc.diversedesign.net/discovering-the-ancient-origin-of-cystic-fibrosis-the-most-common-genetic-disease-in-caucasians/2018-09-07T15:41:00+00:00https://gbc.diversedesign.net/curetis-extends-distribution-agreement-with-beijing-clear-biotech-in-china/2018-10-12T20:25:44+00:00https://gbc.diversedesign.net/only-a-tenth-of-the-human-genome-is-studied/2018-10-25T16:35:11+00:00https://gbc.diversedesign.net/curetis-subsidiary-ares-genetics-teams-up-with-leading-global-pharma-company-in-fight-against-antibiotic-resistance/2018-12-19T19:02:41+00:00https://gbc.diversedesign.net/curetis-subsidiary-ares-genetics-advances-ai-powered-infectious-disease-and-antibiotic-resistance-test/2019-01-08T23:45:31+00:00https://gbc.diversedesign.net/curetis-unyvero-application-cartridges-receive-regulatory-approvals-in-malaysia-and-thailand/2019-01-30T17:41:50+00:00https://gbc.diversedesign.net/curetis-partner-beijing-clear-biotech-submits-filing-for-unyvero-approval-in-china/2019-02-04T16:22:50+00:00https://gbc.diversedesign.net/curetis-subsidiary-ares-genetics-and-qiagen-enter-into-bioinformatics-partnership-to-fight-antimicrobial-resistance/2019-02-18T21:14:31+00:00https://gbc.diversedesign.net/2955/2019-02-20T18:36:31+00:00https://gbc.diversedesign.net/discovery-life-sciences-launches-major-european-expansion/2019-02-20T18:39:37+00:00https://gbc.diversedesign.net/geisinger-to-offer-dna-sequencing-to-all-its-ptients/2019-02-21T20:30:56+00:00https://gbc.diversedesign.net/help-protect-the-breakthroughs-of-tomorrow-www-innovation-com/2019-03-05T00:50:19+00:00https://gbc.diversedesign.net/the-6-most-common-warnings-for-fda-21-cfr-820-noncompliance/2019-03-05T17:44:42+00:00https://gbc.diversedesign.net/u-s-representatives-payne-marchant-and-sewell-introduce-bi-partisan-colorectal-cancer-detection-bill/2019-03-18T15:13:59+00:00https://gbc.diversedesign.net/precision-medicine-starts-with-pathology-pathologists-at-the-center-of-collaboration/2019-03-19T14:47:29+00:00https://gbc.diversedesign.net/curetis-and-menarini-diagnostics-enter-into-strategic-pan-european-exclusive-partnership-for-the-distribution-of-curetis-unyvero/2019-03-26T14:47:07+00:00https://gbc.diversedesign.net/ariana-to-present-data-at-aacr-2019-on-using-artificial-intelligence-to-simulate-patient-stratification-in-clinical-trials-and-identify-companion-biomarkers-for-combination-therapy/2019-03-29T15:36:59+00:00https://gbc.diversedesign.net/vela-diagnostics-submits-ngs-hiv-genotyping-drug-resistance-assay-to-fda/2019-04-03T15:42:07+00:00https://gbc.diversedesign.net/curetis-study-data-presented-at-eccmid-2019-confirm-clinical-benefits-of-unyvero-platform/2019-04-04T22:16:56+00:00https://gbc.diversedesign.net/new-report-shows-crc-screening-rates-increased-when-a-medically-underserved-population-is-offered-epi-procolon-blood-test/2019-05-21T15:21:25+00:00https://gbc.diversedesign.net/curetis-reports-positive-results-from-clinical-validation-study-for-u-s-fda-510k-submission-of-unyvero-lrt-for-bal-samples/2019-05-23T15:21:26+00:00https://gbc.diversedesign.net/new-data-on-curetis-unyvero-lrt-panel-for-pneumonia-to-be-presented-at-asm-microbe-2019/2019-06-04T15:50:54+00:00https://gbc.diversedesign.net/new-clinical-data-support-the-utility-of-epi-procolon-blood-test-for-colorectal-cancer-crc-screening-in-patients-with-lynch-syndrome-ls-the-most-common-hereditary-crc-syndrome/2019-06-18T13:43:33+00:00https://gbc.diversedesign.net/array-biopharmas-triple-drug-combo-could-be-gamechanger-for-colorectal-cancer/2019-07-08T19:09:20+00:00https://gbc.diversedesign.net/epigenomics-ag-receives-medtech-outlooks-2019-top-10-in-vitro-diagnostics-award/2019-07-12T14:55:57+00:00https://gbc.diversedesign.net/curetis-files-for-u-s-fda-510k-clearance-of-unyvero-lower-respiratory-tract-lrt-infection-assay-for-bronchoalveolar-lavage-bal-specimens/2019-07-23T15:54:52+00:00https://gbc.diversedesign.net/study-published-in-american-health-drug-benefits-suggests-that-non-invasive-screening-methods-including-epi-procolon-could-be-a-cost-effective-option-to-help-achieve-target-u-s-colorectal-can/2019-07-24T15:24:31+00:00https://gbc.diversedesign.net/curetis-and-opgen-enter-into-definitive-agreement-to-combine-businesses/2019-09-04T21:37:29+00:00https://gbc.diversedesign.net/asia-pacific-in-vitro-diagnostics-market-is-expected-to-reach-19-0-billion/2019-09-05T16:01:46+00:00https://gbc.diversedesign.net/curetis-group-subsidiary-ares-genetics-signs-rd-and-option-agreement-with-leading-global-ivd-corporation/2019-09-16T17:32:36+00:00https://gbc.diversedesign.net/india-to-enhance-oversight-of-medical-devices/2019-09-26T18:29:42+00:00https://gbc.diversedesign.net/new-blood-test-can-detect-multiple-types-of-cancer/2019-10-01T17:35:27+00:00https://gbc.diversedesign.net/fda-proposes-safer-technologies-program-for-medical-devices-step/2019-10-03T16:02:22+00:00https://gbc.diversedesign.net/opgen-curetis-obtain-u-s-patent-covering-acuitas-lighthouse-software/2019-10-23T17:34:50+00:00https://gbc.diversedesign.net/opgen-announces-stock-offering/2019-10-24T16:10:00+00:00https://gbc.diversedesign.net/curetis-group-company-ares-genetics-launches-ai-powered-molecular-antibiotic-susceptibility-test/2019-10-28T17:14:57+00:00https://gbc.diversedesign.net/fda-grants-de-novo-designation-for-vela-diagnostics-next-generation-sequencing-hiv-1-genotyping-assay/2019-11-07T18:05:16+00:00https://gbc.diversedesign.net/curetis-expects-near-term-u-s-fda-decision-on-510k-clearance-of-unyvero-lrt-for-bal-specimens/2019-11-25T18:43:43+00:00https://gbc.diversedesign.net/epigenomics-ag-reports-on-new-micro-simulation-study-results-published-in-cancer-medicine-indicating-that-epi-procolon-provides-clinically-meaningful-reductions-in-incidence-and-mortality-of-col/2019-12-03T16:19:56+00:00https://gbc.diversedesign.net/ares-genetics-a-curetis-group-company-joins-nvidia-inception-and-amazon-web-services-aws-activate-programs/2019-12-10T18:59:37+00:00https://gbc.diversedesign.net/curetis-receives-u-s-fda-510k-clearance-of-unyvero-lrt-for-bronchoalveolar-lavage-bal-specimens/2019-12-23T19:10:38+00:00https://gbc.diversedesign.net/curetis-launches-recently-fda-cleared-unyvero-lower-respiratory-tract-lrt-pneumonia-pathogen-panel-for-bronchoalveolar-lavage-bal-specimens-in-the-u-s/2020-01-14T17:14:58+00:00https://gbc.diversedesign.net/improving-cancer-screening-programs/2020-01-16T17:20:32+00:00https://gbc.diversedesign.net/the-superbug-crisis-heats-up/2020-01-22T16:44:06+00:00https://gbc.diversedesign.net/curetis-group-company-ares-genetics-and-bgi-group-collaborate-to-offer-next-generation-sequencing-and-pcr-based-coronavirus-2019-ncov-testing-in-europe/2020-01-31T15:58:10+00:00https://gbc.diversedesign.net/gi-societies-issue-updated-colorectal-cancer-screening-recommendations/2020-02-20T20:10:45+00:00https://gbc.diversedesign.net/biopharmaceutical-innovators-lead-the-charge-in-fight-against-coronavirus/2020-02-25T16:04:15+00:00https://gbc.diversedesign.net/centers-for-medicare-medicaid-services-cms-open-national-coverage-determination-ncd-review-process-for-epi-procolon/2020-03-02T15:51:17+00:00https://gbc.diversedesign.net/epigenomics-request-triggers-centers-for-medicare-and-medicaid-services-cms-plan-to-cover-colorectal-cancer-blood-based-biomarker-tests/2020-03-04T17:15:14+00:00https://gbc.diversedesign.net/curetis-n-v-reports-results-of-the-extraordinary-general-meeting/2020-03-10T15:43:06+00:00https://gbc.diversedesign.net/u-s-coronavirus-testing-threatened-by-shortage-of-critical-lab-materials/2020-03-12T17:48:36+00:00https://gbc.diversedesign.net/microrna-signatures-may-aid-in-early-detection-of-lung-cancer/2020-03-12T17:51:29+00:00https://gbc.diversedesign.net/first-of-3-diagnostic-tests-for-coronavirus-covid-19-available-from-biomerieux/2020-03-13T18:31:12+00:00https://gbc.diversedesign.net/curetis-begins-offering-bgis-ce-ivd-rapid-test-kit-for-coronavirus-in-europe/2020-03-16T16:46:47+00:00https://gbc.diversedesign.net/researchers-at-uc-san-diego-evaluating-potential-one-hour-covid-19-diagnostic-test-developed-by-irvine-based-innovator-fluxergy/2020-03-23T17:23:18+00:00https://gbc.diversedesign.net/biomerieux-receives-emergency-use-authorization-for-biofire-covid-19-test/2020-03-27T17:27:03+00:00https://gbc.diversedesign.net/opgen-announces-shareholder-approval-for-business-combination-with-curetis/2020-03-30T18:06:19+00:00https://gbc.diversedesign.net/coronavirus-test-tracker-commercially-available-covid-19-diagnostic-tests/2020-03-31T16:41:02+00:00https://gbc.diversedesign.net/genomictree-to-export-covid-19-diagnostic-kit-to-usa/2020-04-01T15:47:03+00:00https://gbc.diversedesign.net/randox-and-bosch-to-launch-game-changing-vivalytic-point-of-care-poc-coronavirus-test/2020-04-01T16:01:56+00:00https://gbc.diversedesign.net/curetis-and-opgen-complete-business-combination/2020-04-01T22:14:22+00:00https://gbc.diversedesign.net/vela-diagnostics-to-offer-virokey-sars-cov-2-rt-pcr-test-after-completion-of-emergency-use-authorization-eua-validation/2020-04-02T04:45:29+00:00https://gbc.diversedesign.net/emergency-use-application-eua-follows-completion-of-test-validation-with-patient-samples-by-physician-scientists-at-uc-san-diego/2020-04-06T18:52:19+00:00https://gbc.diversedesign.net/bosch-develops-rapid-test-to-combat-coronavirus-infections/2020-04-13T18:44:42+00:00https://gbc.diversedesign.net/opgen-subsidiary-ares-genetics-demonstrates-feasibility-and-potential-of-next-generation-sequencing-ngs-based-antibiotic-susceptibility-testing-ast-in-multi-center-study/2020-04-16T20:52:58+00:00https://gbc.diversedesign.net/opgen-subsidiary-curetis-gmbh-and-karolinska-institute-collaborate-in-study-of-bacterial-co-infections-in-covid-19-pneumonia-patients/2020-04-21T14:49:41+00:00https://gbc.diversedesign.net/vela-diagnostics-coronavirus-rt-pcr-test-provisionally-authorized-by-singapore-regulator/2020-04-23T22:22:56+00:00https://gbc.diversedesign.net/profile-of-a-killer-the-complex-biology-powering-the-coronavirus-pandemic/2020-05-08T18:50:29+00:00https://gbc.diversedesign.net/fda-grants-emergency-use-authorization-for-rutgers-at-home-covid-19-saliva-test/2020-05-08T18:53:29+00:00https://gbc.diversedesign.net/fluxergy-announces-30-million-to-expand-manufacturing-capacity-of-its-one-hour-point-of-care-diagnostic-testing-system-in-response-to-covid-19/2020-05-18T17:08:00+00:00https://gbc.diversedesign.net/gates-backed-at-home-covid-19-testing-program/2020-05-18T17:24:02+00:00https://gbc.diversedesign.net/f-d-a-clears-everlywell-coronavirus-testing-kit-for-use-at-home/2020-05-18T17:28:52+00:00https://gbc.diversedesign.net/biogx-and-bosch-healthcare-solutions-announce-partnership-to-develop-infectious-disease-tests-for-the-vivalytic-platform/2020-06-01T18:14:38+00:00https://gbc.diversedesign.net/opgen-expands-partnership-with-new-york-state-department-of-health-to-detect-antimicrobial-resistant-amr-infections/2020-06-04T17:43:12+00:00https://gbc.diversedesign.net/opgen-unyvero-hospitalized-pneumonia-hpn-panel-rapidly-identifies-bacterial-coinfections-in-covid-19-pneumonia/2020-06-19T18:45:41+00:00https://gbc.diversedesign.net/could-a-blood-observatory-stop-pandemics/2020-07-08T20:57:02+00:00https://gbc.diversedesign.net/modernas-covid-19-vaccine-shows-early-promise-in-phase-i-trial/2020-07-15T20:22:20+00:00https://gbc.diversedesign.net/menarini-silicon-biosystems-partners-with-opgen-to-broaden-distribution-of-cellsearch-platform-in-north-america/2020-07-15T21:34:00+00:00https://gbc.diversedesign.net/u-s-fda-oks-testing-of-pooled-samples-for-covid-19/2020-07-27T16:36:03+00:00https://gbc.diversedesign.net/people-with-hidden-immunity-against-covid-19/2020-07-27T16:41:09+00:00https://gbc.diversedesign.net/opgen-co-markets-covid-19-antibody-test-kit/2020-08-10T16:05:56+00:00https://gbc.diversedesign.net/opgen-group-company-ares-genetics-demonstrates-feasibility-of-clia-compliant-next-generation-sequencing-workflow-for-identification-of-bacterial-pathogens-and-antibiotic-resistance-markers/2020-08-11T20:21:18+00:00https://gbc.diversedesign.net/new-study-published-in-the-journal-of-the-national-cancer-institute-concludes-that-epi-procolon-is-the-test-of-choice-for-the-millions-of-individuals-not-willing-to-participate-in-fit-or-colonos/2020-08-11T20:23:26+00:00https://gbc.diversedesign.net/opgen-announces-ce-ivd-marking-and-commercial-launch-in-europe-of-its-own-developed-molecular-diagnostic-sars-cov-2-kit-with-pulb-for-detection-of-the-virus-causing-covid-19/2020-08-23T21:19:23+00:00https://gbc.diversedesign.net/covid-19-is-transmitted-through-aerosols-we-have-enough-evidence-now-it-is-time-to-act/2020-08-25T19:56:37+00:00https://gbc.diversedesign.net/opgen-group-company-ares-genetics-nominated-for-austrian-innovation-award-for-ai-powered-molecular-antibiotic-susceptibility-test/2020-09-08T14:38:07+00:00https://gbc.diversedesign.net/gtex-consortium-releases-fresh-insights-into-how-dna-differences-govern-gene-expression/2020-09-15T16:11:20+00:00https://gbc.diversedesign.net/opgen-announces-award-of-german-government-grant-funding-to-its-subsidiary-curetis-and-collaborators/2020-09-30T16:07:37+00:00https://gbc.diversedesign.net/opgen-issues-formal-response-to-fdas-requests-for-additional-information-and-expects-near-term-fda-clearance-decision-for-acuitas-amr-gene-panel/2020-10-13T21:06:50+00:00https://gbc.diversedesign.net/opgen-announces-award-of-german-government-grant-funding-to-its-subsidiary-curetis-and-collaborators-2/2020-10-28T14:51:53+00:00https://gbc.diversedesign.net/streck-cell-free-dna-bct-receives-u-s-fda-de-novo-clearance/2020-10-30T16:18:17+00:00https://gbc.diversedesign.net/worlds-fastest-pcr-based-sars-cov-2-test-now-available-on-randox-bosch-vivalytic-poc-analyzer/2020-11-02T17:23:15+00:00https://gbc.diversedesign.net/first-over-the-counter-covid-19-test-gets-fda-clearance/2020-12-16T17:10:28+00:00https://gbc.diversedesign.net/unyvero-lrt-bal-panel-provides-accurate-detection-in-bronchoalveolar-lavage-bal-fluid-allowing-enhanced-diagnosis-of-lower-respiratory-tract-infections/2020-12-17T23:34:57+00:00https://gbc.diversedesign.net/radx-tech-inks-additional-contracts-for-covid-19-tests-and-supplies/2021-01-13T18:12:06+00:00https://gbc.diversedesign.net/epigenomics-ag-plans-to-challenge-national-coverage-determination-ncd-decision-and-unveils-its-next-generation-liquid-biopsy-test-for-colorectal-cancer-screening/2021-01-25T15:19:31+00:00https://gbc.diversedesign.net/mirimus-inc-announces-publication-of-scientific-paper-highlighting-pooled-saliva-based-testing-as-an-effective-cost-efficient-approach-to-covid-19-surveillance-testing-for-schools/2021-02-23T17:28:01+00:00https://gbc.diversedesign.net/opgen-wins-chinese-nmpa-approval-for-the-curetis-unyvero-system/2021-03-02T16:18:45+00:00https://gbc.diversedesign.net/opgen-announces-publication-of-final-study-results-of-unyvero-hpn-panel-for-diagnosis-of-bacterial-co-infections-in-icu-patients-with-covid-19-pneumonia/2021-03-08T23:49:16+00:00https://gbc.diversedesign.net/fda-authorizes-new-device-to-help-diagnose-pediatric-autism/2021-06-02T22:52:32+00:00https://gbc.diversedesign.net/china-embraces-decentralized-clinical-trial-solutions/2021-06-28T17:37:17+00:00https://gbc.diversedesign.net/opgen-announces-prospective-clinical-data-from-unyvero-lrt-bal-and-acuitas-amr-gene-panel-for-isolates-data-presented-at-world-microbe-forum/2021-06-30T16:32:22+00:00https://gbc.diversedesign.net/parexel-snapped-up-again-as-goldman-sachs-eqt-spend-8-5b-on-the-cro/2021-07-08T14:47:24+00:00https://gbc.diversedesign.net/wcg-guns-for-a-100m-ipo-amid-a-boon-in-the-cro-sector-as-it-recovers-from-covid-chaos/2021-07-08T14:51:26+00:00https://gbc.diversedesign.net/withdraw-of-fda-eua-for-cdc-2019-novel-coronavirus-rt-pcr-diagnostic-panel/2021-07-27T19:15:53+00:00https://gbc.diversedesign.net/opgen-achieves-key-development-milestone-with-curetis-unyvero-a30-rq-platform-program/2021-08-03T21:11:50+00:00https://gbc.diversedesign.net/gbc-contributes-to-nci-cptac-publication-a-proteogenomic-portrait-of-lung-squamous-cell-carcinoma/2021-08-09T21:15:27+00:00https://gbc.diversedesign.net/opgen-announces-data-from-prospective-randomized-controlled-multicenter-clinical-study-using-the-unyvero-hpn-panel-for-hospitalized-patients-with-suspicion-of-pneumonia/2021-09-16T15:22:26+00:00https://gbc.diversedesign.net/opgen-initiates-clinical-trial-for-unyvero-urinary-tract-infection-uti-panel/2021-10-02T02:34:41+00:00https://gbc.diversedesign.net/opgen-receives-fda-clearance-for-acuitas-amr-gene-panel/2021-10-04T16:49:48+00:00https://gbc.diversedesign.net/memorandum-of-understanding-signed-by-nci-fda-and-hrsa-to-bring-cancer-diagnostic-devices-closer-to-patients-particularly-members-of-medically-underserved-and-geographically-isolated-communities/2021-10-07T15:36:59+00:00https://gbc.diversedesign.net/a-biospecimen-crisis-in-biotech/2021-10-07T15:45:44+00:00https://gbc.diversedesign.net/a-grim-diagnosis-half-the-worlds-population-has-limited-access-to-diagnostics/2021-10-11T15:29:14+00:00https://gbc.diversedesign.net/could-the-gut-microbiome-be-linked-to-autism/2021-11-23T17:08:27+00:00https://gbc.diversedesign.net/autism-related-dietary-preferences-mediate-autism-gut-microbiome-associations/2021-11-23T17:12:30+00:00https://gbc.diversedesign.net/fred-hutchinson-cancer-research-center-specimen-acquisition-network-san-data-acquisition-network-services-now-available-to-the-university-of-washington-uw-institute-of-translation-health-science/2022-01-28T19:40:25+00:00https://gbc.diversedesign.net/opgen-announces-interim-analysis-results-from-clinical-trial-for-unyvero-urinary-tract-infection-panel/2022-04-05T15:39:49+00:00https://gbc.diversedesign.net/neonatal-diagnostics-company-infandx-ag-launches-us-operations/2022-04-17T22:03:19+00:00https://gbc.diversedesign.net/neonatal-diagnostics-company-infandx-ag-completes-two-year-patient-follow-up-in-banon-study/2022-05-26T16:44:43+00:00https://gbc.diversedesign.net/opgen-announces-publication-of-results-from-major-clinical-study-using-unyvero-hospitalized-pneumonia-hpn-panel-in-the-lancet-respiratory-medicine/2022-05-26T17:18:50+00:00https://gbc.diversedesign.net/opgen-announces-1000th-patient-sample-enrolled-in-clinical-trial-for-unyvero-urinary-tract-infection-panel/2022-06-22T12:46:07+00:00https://gbc.diversedesign.net/elitechgroup-and-infandx-ag-to-collaborate-on-the-development-and-manufacturing-of-hypoxe-neonatal-care-test-for-clinical-laboratories/2022-07-27T15:13:23+00:00https://gbc.diversedesign.net/opgen-launches-ares-sequencing-services-in-the-u-s-from-its-rockville-maryland-laboratory/2022-08-26T13:48:59+00:00https://gbc.diversedesign.net/opgen-announced-the-signing-of-an-rd-collaboration-agreement-with-find-the-global-alliance-for-diagnostics/2022-09-20T15:19:23+00:00https://gbc.diversedesign.net/european-companies-poised-to-gain-as-eu-commission-blocks-illumina-grail-deal/2022-09-22T16:17:01+00:00https://gbc.diversedesign.net/opgen-announces-successful-completion-of-clinical-trial-enrollment-for-unyvero-urinary-tract-infection-panel/2022-10-03T21:51:36+00:00https://gbc.diversedesign.net/infandx-ag-reports-successful-validation-of-biomarker-panels-for-the-early-detection-of-hypoxic-ischemic-encephalopathy/2022-10-12T18:39:22+00:00https://gbc.diversedesign.net/opgen-subsidiary-curetis-and-bioversys-sign-collaboration-agreement-for-clinical-trial-support-bv100-rifabutin-to-treat-carbapenem-resistant-acinetobacter-baumannii-crab-infections/2022-10-25T18:50:49+00:00https://gbc.diversedesign.net/infandx-tackles-early-detection-of-hypoxic-ischemic-encephalopathy/2022-11-15T16:38:27+00:00https://gbc.diversedesign.net/opgen-announces-positive-top-line-data-from-clinical-trial-for-unyvero-urinary-tract-infection-uti-panel/2022-12-13T15:14:06+00:00https://gbc.diversedesign.net/qvin-diagnostic-device-receives-fda-approval-in-thailand/2023-02-15T19:40:29+00:00https://gbc.diversedesign.net/precision-for-medicine-biobank-partnering-for-clinical-trial-assay-cdx-development-and-high-throughput-ihc-ngs-screening/2023-03-14T19:55:36+00:00https://gbc.diversedesign.net/national-cancer-plan/2023-04-03T16:50:53+00:00https://gbc.diversedesign.net/opgen-submits-de-novo-request-to-the-u-s-fda-for-unyvero-urinary-tract-infection-panel/2023-04-18T20:57:33+00:00https://gbc.diversedesign.net/pan-cancer-study-reveals-epigenomic-drivers-for-cancer-development-and-progression/2023-11-06T17:36:07+00:00https://gbc.diversedesign.net/klas-research-u-s-digital-pathology-report-confirms-philips-as-one-of-the-industrys-leading-players/2023-11-30T18:25:45+00:00https://gbc.diversedesign.net/bacteria-subtype-linked-to-growth-in-up-to-50-of-human-colorectal-cancers/2024-03-25T18:41:07+00:00https://gbc.diversedesign.net/fred-hutch-unveils-results-of-new-blood-test-that-detects-colon-cancer/2024-03-25T20:36:02+00:00https://gbc.diversedesign.net/teal-health-completes-clinical-trial-at-record-speed-and-receives-fda-breakthrough-designation-for-its-at-home-cervical-cancer-screening-device-the-teal-wand/2024-09-04T17:30:04+00:00https://gbc.diversedesign.net/biotech-firm-recursion-to-buy-smaller-peer-exscientia/2024-09-04T17:33:45+00:00https://gbc.diversedesign.net/january-is-cervical-cancer-awareness-month/2025-01-22T18:38:28+00:00https://gbc.diversedesign.net/muse-microscopy-showcasing-smartpath-muse-technology/2025-01-27T21:44:51+00:00https://gbc.diversedesign.net/food-and-drug-administration-announces-the-availability-of-new-draft-guidance-for-industry-e6r3-guideline-for-good-clinical-practic/2025-01-30T19:23:32+00:00https://gbc.diversedesign.net/gbc-partners-with-boudicca-dx-to-become-a-one-stop-global-shop-for-strategy-and-execution-for-medical-device-in-vitro-diagnostic-companies/2025-02-12T20:07:02+00:00https://gbc.diversedesign.net/guardant-healths-shield-colorectal-cancer-blood-test-garners-cms-advanced-diagnostic-status/2025-03-11T19:02:01+00:00https://gbc.diversedesign.net/teal-health-unveils-landmark-study-results-showing-teal-wand-self-collected-samples-match-clinician-collected-samples/2025-03-20T17:19:31+00:00https://gbc.diversedesign.net/mainz-biomed-enrolls-first-patient-in-its-eaarly-detect-2-clinical-study/2025-03-27T17:32:44+00:00https://gbc.diversedesign.net/federal-court-vacates-fda-rule-on-laboratory-developed-testing-ldt-services/2025-04-03T16:28:34+00:00https://gbc.diversedesign.net/samantree-histolog-scanner/2025-04-03T19:10:42+00:00https://gbc.diversedesign.net/quest-diagnostics-launches-new-ad-detect-blood-test-to-aid-in-confirming-alzheimers-disease/2025-04-10T15:10:51+00:00https://gbc.diversedesign.net/inbiomes-bacterial-identification-system-secures-ivdr-certification/2025-04-15T19:34:18+00:00https://gbc.diversedesign.net/gbc-attending-life-science-innovation-northwest-lsinw-2025-in-seattle-wa-4-23-25-to-4-24-25/2025-04-18T00:57:30+00:00https://gbc.diversedesign.net/global-bioclinical-is-attending-the-american-society-of-clinical-oncology-asco-2025-annual-meeting/2025-05-27T16:30:32+00:00